Motavizumab|677010-34-3|(MEDI-524)-陌孚医药/Medlife

您当前的位置：

Motavizumab (Synonyms: MEDI-524)

目录号: PL11102 纯度: ≥98%

CAS No. :677010-34-3

商品编号	规格	价格	会员价
PL11102-1mg	1mg	¥6429.09	请登录
PL11102-5mg	5mg	¥15825.45	请登录
PL11102-10mg	10mg	询价	询价
PL11102-50mg	50mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Motavizumab
中文别名	莫维珠单抗;MOTAVIZUMAB ( 莫维组单抗 );莫维组单抗
英文名称	Motavizumab
英文别名	Motavizumab;Numax;(5S,8S,11S,14S,17S,20S,23S,26R,29S,32S,35S)-5-Amino-20-[(2S)-2-butanyl]-6,13,16,19,24,31-hexahydroxy;MOTAVIZUMAB
Cas No.	677010-34-3
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.

产品详情

Motavizumab (MEDI-524) 是一种 anti-human RSV (呼吸道合胞病毒) 单克隆抗体。Motavizumab 可用于高危婴儿的呼吸道合胞病毒感染的研究。

生物活性

Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.

性状

Liquid

体外研究(In Vitro)

Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription.
Motavizumab inhibits F protein-mediated cell-to-cell fusion. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

ClinicalTrial

参考文献

[1]. Mejías A, et al. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. Virol J. 2007 Oct 25;4:109.
[2]. Huang K, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010 Aug;84(16):8132-40.

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation